Engineering of Lactobacillus jensenii to secrete RANTES and a CCR5 antagonist analogue as live HIV-1 blockers

Luca Vangelista, Massimiliano Secchi, Xiaowen Liu, Angela Bachi, Letong Jia, Qiang Xu, Paolo Lusso

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

The development of effective microbicides for the prevention of HIV-1 sexual transmission represents a primary goal for the control of AIDS epidemics worldwide. A promising strategy is the use of bacteria belonging to the vaginal microbiota as live microbicides for the topical production of HIV-1 inhibitors. We have engineered a human vaginal isolate of Lactobacillus jensenii to secrete the anti-HIV-1 chemokine RANTES, as well as C1C5 RANTES, a mutated analogue that acts as a CCR5 antagonist and therefore is devoid of proinflammatory activity. Full-length wild-type RANTES and C1C5 RANTES secreted by L. jensenii were purified to homogeneity and shown to adopt a correctly folded conformation. Both RANTES variants were shown to inhibit HIV-1 infection in CD4+ T cells and macrophages, displaying strong activity against HIV-1 isolates of different genetic subtypes. This work provides proof of principle for the use of L. jensenii-produced C1C5 RANTES to block HIV-1 infection of CD4+ T cells and macrophages, setting the basis for the development of a live anti-HIV-1 microbicide targeting CCR5 in an antagonistic manner.

Original languageEnglish
Pages (from-to)2994-3001
Number of pages8
JournalAntimicrobial Agents and Chemotherapy
Volume54
Issue number7
DOIs
Publication statusPublished - 2010
Externally publishedYes

Fingerprint

Chemokine CCL5
Lactobacillus
HIV-1
Anti-Infective Agents
HIV Infections
Macrophages
T-Lymphocytes
Local Anti-Infective Agents
Microbiota
Chemokines
Acquired Immunodeficiency Syndrome
Bacteria

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases
  • Medicine(all)

Cite this

Engineering of Lactobacillus jensenii to secrete RANTES and a CCR5 antagonist analogue as live HIV-1 blockers. / Vangelista, Luca; Secchi, Massimiliano; Liu, Xiaowen; Bachi, Angela; Jia, Letong; Xu, Qiang; Lusso, Paolo.

In: Antimicrobial Agents and Chemotherapy, Vol. 54, No. 7, 2010, p. 2994-3001.

Research output: Contribution to journalArticle

Vangelista, Luca ; Secchi, Massimiliano ; Liu, Xiaowen ; Bachi, Angela ; Jia, Letong ; Xu, Qiang ; Lusso, Paolo. / Engineering of Lactobacillus jensenii to secrete RANTES and a CCR5 antagonist analogue as live HIV-1 blockers. In: Antimicrobial Agents and Chemotherapy. 2010 ; Vol. 54, No. 7. pp. 2994-3001.
@article{4e42e20a641d4774b5810ce3d9f8fcc5,
title = "Engineering of Lactobacillus jensenii to secrete RANTES and a CCR5 antagonist analogue as live HIV-1 blockers",
abstract = "The development of effective microbicides for the prevention of HIV-1 sexual transmission represents a primary goal for the control of AIDS epidemics worldwide. A promising strategy is the use of bacteria belonging to the vaginal microbiota as live microbicides for the topical production of HIV-1 inhibitors. We have engineered a human vaginal isolate of Lactobacillus jensenii to secrete the anti-HIV-1 chemokine RANTES, as well as C1C5 RANTES, a mutated analogue that acts as a CCR5 antagonist and therefore is devoid of proinflammatory activity. Full-length wild-type RANTES and C1C5 RANTES secreted by L. jensenii were purified to homogeneity and shown to adopt a correctly folded conformation. Both RANTES variants were shown to inhibit HIV-1 infection in CD4+ T cells and macrophages, displaying strong activity against HIV-1 isolates of different genetic subtypes. This work provides proof of principle for the use of L. jensenii-produced C1C5 RANTES to block HIV-1 infection of CD4+ T cells and macrophages, setting the basis for the development of a live anti-HIV-1 microbicide targeting CCR5 in an antagonistic manner.",
author = "Luca Vangelista and Massimiliano Secchi and Xiaowen Liu and Angela Bachi and Letong Jia and Qiang Xu and Paolo Lusso",
year = "2010",
doi = "10.1128/AAC.01492-09",
language = "English",
volume = "54",
pages = "2994--3001",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "7",

}

TY - JOUR

T1 - Engineering of Lactobacillus jensenii to secrete RANTES and a CCR5 antagonist analogue as live HIV-1 blockers

AU - Vangelista, Luca

AU - Secchi, Massimiliano

AU - Liu, Xiaowen

AU - Bachi, Angela

AU - Jia, Letong

AU - Xu, Qiang

AU - Lusso, Paolo

PY - 2010

Y1 - 2010

N2 - The development of effective microbicides for the prevention of HIV-1 sexual transmission represents a primary goal for the control of AIDS epidemics worldwide. A promising strategy is the use of bacteria belonging to the vaginal microbiota as live microbicides for the topical production of HIV-1 inhibitors. We have engineered a human vaginal isolate of Lactobacillus jensenii to secrete the anti-HIV-1 chemokine RANTES, as well as C1C5 RANTES, a mutated analogue that acts as a CCR5 antagonist and therefore is devoid of proinflammatory activity. Full-length wild-type RANTES and C1C5 RANTES secreted by L. jensenii were purified to homogeneity and shown to adopt a correctly folded conformation. Both RANTES variants were shown to inhibit HIV-1 infection in CD4+ T cells and macrophages, displaying strong activity against HIV-1 isolates of different genetic subtypes. This work provides proof of principle for the use of L. jensenii-produced C1C5 RANTES to block HIV-1 infection of CD4+ T cells and macrophages, setting the basis for the development of a live anti-HIV-1 microbicide targeting CCR5 in an antagonistic manner.

AB - The development of effective microbicides for the prevention of HIV-1 sexual transmission represents a primary goal for the control of AIDS epidemics worldwide. A promising strategy is the use of bacteria belonging to the vaginal microbiota as live microbicides for the topical production of HIV-1 inhibitors. We have engineered a human vaginal isolate of Lactobacillus jensenii to secrete the anti-HIV-1 chemokine RANTES, as well as C1C5 RANTES, a mutated analogue that acts as a CCR5 antagonist and therefore is devoid of proinflammatory activity. Full-length wild-type RANTES and C1C5 RANTES secreted by L. jensenii were purified to homogeneity and shown to adopt a correctly folded conformation. Both RANTES variants were shown to inhibit HIV-1 infection in CD4+ T cells and macrophages, displaying strong activity against HIV-1 isolates of different genetic subtypes. This work provides proof of principle for the use of L. jensenii-produced C1C5 RANTES to block HIV-1 infection of CD4+ T cells and macrophages, setting the basis for the development of a live anti-HIV-1 microbicide targeting CCR5 in an antagonistic manner.

UR - http://www.scopus.com/inward/record.url?scp=77953756392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953756392&partnerID=8YFLogxK

U2 - 10.1128/AAC.01492-09

DO - 10.1128/AAC.01492-09

M3 - Article

VL - 54

SP - 2994

EP - 3001

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 7

ER -